Clinical Trials Browser

Phase 2 × Hemangiosarcoma × regorafenib × Clear all

NCT02048722 2022-04-25

Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Phase 2 Completed

31 enrolled 15 charts

Hemangiosarcoma, Sarcoma